2025-02-012026-01-312026-01-31false11173964ARSAN MEDICAL LTD2026-04-2986220falseiso4217:GBPxbrli:pure111739642025-01-31111739642026-01-31111739642025-02-012026-01-31111739642024-01-31111739642025-01-31111739642024-02-012025-01-3111173964bus:SmallEntities2025-02-012026-01-3111173964bus:AuditExempt-NoAccountantsReport2025-02-012026-01-3111173964bus:FullAccounts2025-02-012026-01-3111173964bus:PrivateLimitedCompanyLtd2025-02-012026-01-3111173964core:WithinOneYear2026-01-3111173964core:AfterOneYear2026-01-3111173964core:WithinOneYear2025-01-3111173964core:AfterOneYear2025-01-3111173964core:ShareCapital2026-01-3111173964core:SharePremium2026-01-3111173964core:RevaluationReserve2026-01-3111173964core:OtherReservesSubtotal2026-01-3111173964core:RetainedEarningsAccumulatedLosses2026-01-3111173964core:ShareCapital2025-01-3111173964core:SharePremium2025-01-3111173964core:RevaluationReserve2025-01-3111173964core:OtherReservesSubtotal2025-01-3111173964core:RetainedEarningsAccumulatedLosses2025-01-3111173964core:LandBuildings2026-01-3111173964core:PlantMachinery2026-01-3111173964core:Vehicles2026-01-3111173964core:FurnitureFittings2026-01-3111173964core:OfficeEquipment2026-01-3111173964core:NetGoodwill2026-01-3111173964core:IntangibleAssetsOtherThanGoodwill2026-01-3111173964core:ListedExchangeTraded2026-01-3111173964core:UnlistedNon-exchangeTraded2026-01-3111173964core:LandBuildings2025-01-3111173964core:PlantMachinery2025-01-3111173964core:Vehicles2025-01-3111173964core:FurnitureFittings2025-01-3111173964core:OfficeEquipment2025-01-3111173964core:NetGoodwill2025-01-3111173964core:IntangibleAssetsOtherThanGoodwill2025-01-3111173964core:ListedExchangeTraded2025-01-3111173964core:UnlistedNon-exchangeTraded2025-01-3111173964core:LandBuildings2025-02-012026-01-3111173964core:PlantMachinery2025-02-012026-01-3111173964core:Vehicles2025-02-012026-01-3111173964core:FurnitureFittings2025-02-012026-01-3111173964core:OfficeEquipment2025-02-012026-01-3111173964core:NetGoodwill2025-02-012026-01-3111173964core:IntangibleAssetsOtherThanGoodwill2025-02-012026-01-3111173964core:ListedExchangeTraded2025-02-012026-01-3111173964core:UnlistedNon-exchangeTraded2025-02-012026-01-3111173964core:MoreThanFiveYears2025-02-012026-01-3111173964core:Non-currentFinancialInstruments2026-01-3111173964core:Non-currentFinancialInstruments2025-01-3111173964dpl:CostSales2025-02-012026-01-3111173964dpl:DistributionCosts2025-02-012026-01-3111173964core:LandBuildings2025-02-012026-01-3111173964core:PlantMachinery2025-02-012026-01-3111173964core:Vehicles2025-02-012026-01-3111173964core:FurnitureFittings2025-02-012026-01-3111173964core:OfficeEquipment2025-02-012026-01-3111173964dpl:AdministrativeExpenses2025-02-012026-01-3111173964core:NetGoodwill2025-02-012026-01-3111173964core:IntangibleAssetsOtherThanGoodwill2025-02-012026-01-3111173964dpl:GroupUndertakings2025-02-012026-01-3111173964dpl:ParticipatingInterests2025-02-012026-01-3111173964dpl:GroupUndertakingscore:ListedExchangeTraded2025-02-012026-01-3111173964core:ListedExchangeTraded2025-02-012026-01-3111173964dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2025-02-012026-01-3111173964core:UnlistedNon-exchangeTraded2025-02-012026-01-3111173964dpl:CostSales2024-02-012025-01-3111173964dpl:DistributionCosts2024-02-012025-01-3111173964core:LandBuildings2024-02-012025-01-3111173964core:PlantMachinery2024-02-012025-01-3111173964core:Vehicles2024-02-012025-01-3111173964core:FurnitureFittings2024-02-012025-01-3111173964core:OfficeEquipment2024-02-012025-01-3111173964dpl:AdministrativeExpenses2024-02-012025-01-3111173964core:NetGoodwill2024-02-012025-01-3111173964core:IntangibleAssetsOtherThanGoodwill2024-02-012025-01-3111173964dpl:GroupUndertakings2024-02-012025-01-3111173964dpl:ParticipatingInterests2024-02-012025-01-3111173964dpl:GroupUndertakingscore:ListedExchangeTraded2024-02-012025-01-3111173964core:ListedExchangeTraded2024-02-012025-01-3111173964dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2024-02-012025-01-3111173964core:UnlistedNon-exchangeTraded2024-02-012025-01-3111173964core:NetGoodwill2026-01-3111173964core:IntangibleAssetsOtherThanGoodwill2026-01-3111173964core:LandBuildings2026-01-3111173964core:PlantMachinery2026-01-3111173964core:Vehicles2026-01-3111173964core:FurnitureFittings2026-01-3111173964core:OfficeEquipment2026-01-3111173964core:AfterOneYear2026-01-3111173964core:WithinOneYear2026-01-3111173964core:ListedExchangeTraded2026-01-3111173964core:UnlistedNon-exchangeTraded2026-01-3111173964core:ShareCapital2026-01-3111173964core:SharePremium2026-01-3111173964core:RevaluationReserve2026-01-3111173964core:OtherReservesSubtotal2026-01-3111173964core:RetainedEarningsAccumulatedLosses2026-01-3111173964core:NetGoodwill2025-01-3111173964core:IntangibleAssetsOtherThanGoodwill2025-01-3111173964core:LandBuildings2025-01-3111173964core:PlantMachinery2025-01-3111173964core:Vehicles2025-01-3111173964core:FurnitureFittings2025-01-3111173964core:OfficeEquipment2025-01-3111173964core:AfterOneYear2025-01-3111173964core:WithinOneYear2025-01-3111173964core:ListedExchangeTraded2025-01-3111173964core:UnlistedNon-exchangeTraded2025-01-3111173964core:ShareCapital2025-01-3111173964core:SharePremium2025-01-3111173964core:RevaluationReserve2025-01-3111173964core:OtherReservesSubtotal2025-01-3111173964core:RetainedEarningsAccumulatedLosses2025-01-3111173964core:NetGoodwill2024-01-3111173964core:IntangibleAssetsOtherThanGoodwill2024-01-3111173964core:LandBuildings2024-01-3111173964core:PlantMachinery2024-01-3111173964core:Vehicles2024-01-3111173964core:FurnitureFittings2024-01-3111173964core:OfficeEquipment2024-01-3111173964core:AfterOneYear2024-01-3111173964core:WithinOneYear2024-01-3111173964core:ListedExchangeTraded2024-01-3111173964core:UnlistedNon-exchangeTraded2024-01-3111173964core:ShareCapital2024-01-3111173964core:SharePremium2024-01-3111173964core:RevaluationReserve2024-01-3111173964core:OtherReservesSubtotal2024-01-3111173964core:RetainedEarningsAccumulatedLosses2024-01-3111173964core:AfterOneYear2025-02-012026-01-3111173964core:WithinOneYear2025-02-012026-01-3111173964core:Non-currentFinancialInstrumentscore:CostValuation2025-02-012026-01-3111173964core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-02-012026-01-3111173964core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-02-012026-01-3111173964core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-02-012026-01-3111173964core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-02-012026-01-3111173964core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-02-012026-01-3111173964core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-02-012026-01-3111173964core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-02-012026-01-3111173964core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-02-012026-01-3111173964core:Non-currentFinancialInstrumentscore:CostValuation2026-01-3111173964core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2026-01-3111173964core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2026-01-3111173964core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2026-01-3111173964core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2026-01-3111173964core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2026-01-3111173964core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2026-01-3111173964core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2026-01-3111173964core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2026-01-3111173964core:Non-currentFinancialInstrumentscore:CostValuation2025-01-3111173964core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-01-3111173964core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-01-3111173964core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-01-3111173964core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-01-3111173964core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-01-3111173964core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-01-3111173964core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-01-3111173964core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-01-3111173964bus:Director12025-02-012026-01-3111173964bus:Director22025-02-012026-01-31

ARSAN MEDICAL LTD

Registered Number
11173964
(England and Wales)

Unaudited Financial Statements for the Year ended
31 January 2026

ARSAN MEDICAL LTD
Company Information
for the year from 1 February 2025 to 31 January 2026

Directors

ARSAN, Matay
YOUSIF, Lema

Registered Address

3 Spring Head Road
Kemsing
Sevenoaks
TN15 6QL

Registered Number

11173964 (England and Wales)
ARSAN MEDICAL LTD
Balance Sheet as at
31 January 2026

Notes

2026

2025

£

£

£

£

Fixed assets
Tangible assets3616-
616-
Current assets
Debtors433,01016,648
Cash at bank and on hand70,74765,384
103,75782,032
Creditors amounts falling due within one year5(27,893)(16,736)
Net current assets (liabilities)75,86465,296
Total assets less current liabilities76,48065,296
Net assets76,48065,296
Capital and reserves
Called up share capital22
Profit and loss account76,47865,294
Shareholders' funds76,48065,296
The financial statements were approved and authorised for issue by the Board of Directors on 29 April 2026, and are signed on its behalf by:
ARSAN, Matay
Director
YOUSIF, Lema
Director

Registered Company No. 11173964
ARSAN MEDICAL LTD
Notes to the Financial Statements
for the year ended 31 January 2026

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in accordance with the Companies Act 2006 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.
Revenue from sale of goods
Revenue from the sale of goods is recognised when the company has transferred to the buyer the significant risks and rewards of ownership of the goods, usually when goods are delivered and legal title has passed. Providing the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the company and the costs incurred or to be incurred in respect of the transition can be measured reliably.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Tangible fixed assets and depreciation
All fixed assets are initially recorded at cost. Property, plant and equipment is used in the company's principal activity for the production and supply of goods or for administrative purposes and is stated in the balance sheet under the historic cost model. This model requires the assets to be stated at cost less amounts in respect of depreciation and less any accumulated impairment losses. Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value (which is the expected amount that would currently be obtained from disposal of an asset, after deducting the estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life), over the useful economic life of the respective asset as follows:

Straight line (years)
Office Equipment4
2.Average number of employees

20262025
Average number of employees during the year22
3.Tangible fixed assets

Office Equipment

Total

££
Cost or valuation
At 01 February 254,9494,949
Additions822822
At 31 January 265,7715,771
Depreciation and impairment
At 01 February 254,9494,949
Charge for year206206
At 31 January 265,1555,155
Net book value
At 31 January 26616616
At 31 January 25--
4.Debtors: amounts due within one year

2026

2025

££
Trade debtors / trade receivables-16,648
Other debtors33,010-
Total33,01016,648
5.Creditors: amounts due within one year

2026

2025

££
Taxation and social security24,90214,184
Other creditors591632
Accrued liabilities and deferred income2,4001,920
Total27,89316,736
6.Directors advances, credits and guarantees
As at the 31 January 2026, there were amounts due to the Company by the director of £33,010 (2025: £nil). There were no terms attached to the loan and no interest was charged. The loan was fully repaid within 9 months of the year end.